

Clerk of the House of Representatives  
 Legislative Resource Center  
 B-106 Cannon Building  
 Washington, DC 20515

Secretary of the Senate  
 Office of Public Records  
 232 Hart Building  
 Washington, DC 20510

SECRETARY OF  
 03 AUG 25 F

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Ryan, Phillips, Utrecht, & MacKinnon			
2. Address <input type="checkbox"/> Check if different than previously reported 1133 Connecticut Avenue, NW, Suite 300			
3. Principal Place of Business (if different from line 2) City: Washington State/Zip (or Country) DC 20036			
4. Contact Name Rodney Hoppe	Telephone 202-293-1177	E-mail (optional)	5. Senate ID #
7. Client Name <input type="checkbox"/> Self Pfizer Inc.			6. House ID # 306800

**TYPE OF REPORT** 8. Year 2003 Midyear (January 1-June 30) x **OR** Year End (July 1-Dec)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  Termination Date \_\_\_\_\_ 11. No Lobbyin

## INCOME OR EXPENSES – Complete Either Line 12 OR Line 13

<p><b>12. Lobbying Firms</b></p> <p><b>INCOME</b> relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> \$ <u>60,000</u>  <small>Income (nearest \$20,000)</small></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p><b>EXPENSES</b> relating to lobbying activities for this rep were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> \$ _____  <small>Expenses (neare:</small></p> <p><b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of</p> <p><input type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definit</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 603 Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162 Internal Revenue Code</p>
--	---

Signature



8/15/2003

1007 - 11/11/15 01.0/200  
Printed Name and Title Rodney Hoppe, Partner

LD-2 (REV. 6/98)

P

Registrant Name Ryan, Phillips, Utrecht & MacKinnon

Client Name Pfizer Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the : engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each cod** information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Pharmaceutical Market Access Act of 2003[H.R.2427.EH], all provisions

Medicare Rx Drug Discount and Security Act of 2003[S.778.IS], all provisions

17. House(s) of Congress and Federal Agencies contacted

Check if None

U.S. House

U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Matt Berzok	
Rodney Hoppe	
Jeffrey M. MacKinnon	
William D. Phillips	
Mark Planning	
Thomas M. Ryan	
Joseph V. Vasapoli	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Printed Name and Title Rodney Hoppe- Partner

Form LD-2 (Rev. 6/98)

Page

Registrant Name Ryan, Phillips, Utrecht & MacKinnon

Client Name Pfizer Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each cod information as requested. Attach additional page(s) as needed.**

15. General issue area code PHA (One per page)

16. Specific lobbying issues

- Legislation on issues pertaining to proposed Medical Prescription Drug Benefits.
- Legislation on issues regarding FDA regulation of prescription drugs.
- Pharmaceutical Market Access Act of 2003[H.R.2427.EH], all provisions
- Medicare Rx Drug Discount and Security Act of 2003[S.778.IS], all provisions
- United States Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003 [H.R.1298.PCS]

17. House(s) of Congress and Federal Agencies contacted  Check if None

- U.S. House
- U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Matt Berzok	-----
Rodney Hoppe	-----
Jeffrey M. MacKinnon	-----
William D. Phillips	-----
Mark Planning	-----
Thomas M. Ryan	-----
Joseph V. Vasapoli	-----

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_

Date \_\_\_\_\_

Printed Name and Title Rodney Hoppe- Partner

Page :